The External Validation of the Cardiovascular Risk Equation for Renal Transplant Recipients

Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

(2012) J. O. Medina Pestana et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Cardiovascular Risk Calculator for Renal Transplant Recipients

(2012) Inga Soveri et al.   TRANSPLANTATION

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

(2011) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Framingham Risk Score and Novel Cardiovascular Risk Factors Underpredict Major Adverse Cardiac Events in Kidney Transplant Recipients

(2011) Samuel A. Silver et al.   TRANSPLANTATION

Predicting Coronary Heart Disease after Kidney Transplantation: Patient Outcomes in Renal Transplantation (PORT) Study

(2010) A. K. Israni et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

(2010) A. Durrbach et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

(2010) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION